前列腺癌(PCa)是男性第二位最常见的肿瘤死亡原因。由于绝大多数患者采用激素进行治疗,所以也多死于非激素依赖性前列腺癌(HRPC)。尽管这类疾病很多,但对外科或药物去势后肿瘤进展的患者根本没有公认的治疗标准,而且对激素治疗后全身治疗的选择这一问题历来都是紧迫的。长期以来细胞毒化疗对PCa作用甚微,无数过去的治疗研究结果令人失望,其客观有效率常低于10％。但是最近5年来除了完善方法学规则外,主要通过已知的细胞抑制剂重新联合进行治疗并取得了一些充满希望的结果。 Prostate cancer (PCa) is the second most common cause of cancer death in men. As the vast majority of patients treated with hormones, they also died of more hormone-independent prostate cancer (HRPC). Despite the large number of such diseases, there is simply no accepted standard of care for patients undergoing surgical or drug-induced tumor progression and the issue of systemic treatment after hormone therapy has historically been pressing. For a long time cytotoxic chemotherapy has little effect on PCa, numerous past treatment results disappointing, the objective efficiency is often less than 10%. However, in the last five years, in addition to perfecting the rules of the methodology, the treatment has been reformed mainly by known cytostatics and some promising results have been obtained.